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INTRODUCTION
Parasitic diseases are widespread throughout the de-
veloping world and are associated with a heavy burden
of morbidity and mortality. Human filarial nematodes,
transmitted by arthropod vectors, are endemic in tropical
and sub-tropical regions around the world1. Lymphatic
filariasis (LF) is one of the oldest and most debilitating
diseases throughout the world and millions of people suf-
fer from this disease. In 1995, the World Health Organi-
zation (WHO) ranked LF as the second-leading cause of
long-term chronic disability worldwide2.
LF is estimated to infect over 120 million people in
at least 80 countries of the world. More than one billion
people are at risk of getting affected with this life-threat-
ening disease3. In India, it is a major public health prob-
lem accounting for 40% of the world disease burden4–5.
India has been one-third of the infected people from this
disease and rests are in the South Asia, Western Pacific
and in the part of Central America. LF has been found
one of the potentially eradicable diseases. Therefore, in
the 50th meeting of the World Health Assembly in May
1997 it was announced to eliminate LF by the year 20206.
Various elimination programmes have been launched
in India and globally to eradicate this disease. In 1998,
WHO initiated a global programme for elimination of
lymphatic filariasis (GPELF) employing mass drug ad-
ministration (MDA) of annual single dose of a combina-
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tion of diethyl carbamazine citrate (DEC) (6 mg/kg) or
Ivermectin and Albendazole (400 mg)7 and Albendazole/
Ivermectin in the endemic areas where the disease is co-
endemic with onchocerciasis for at least five years8. Sev-
eral recent studies suggest that the co-administration of
these two drugs for LF is very effective. These combina-
tions produced prolonged suppression of microfilaraemia
(mf) than either drug alone9–11. These drugs are able to
kill the parasitic worms available in the blood, but are not
completely effective against the adult worms. Moreover,
recent studies suggest that albendazole is getting resis-
tance for treatment of this disease12–13.
To eradicate LF globally, research strategy is needed
to develop or design other effective drugs and drug tar-
gets, new methods for vector control and diagnostic tools
and techniques. At the same time, the treatment of LF
requires supportive or disease-specific clinical care, and
patient education with counseling to avoid this disease.
Moreover, major filarial research should have to address
the obstacles to eliminate LF and the outcome of post-
MDA surveillance of various active LF elimination
programmes. This outcome data may help to further
modify (if needed) the current strategies for effective
outcome of several LF programmes. These data can be
stored and made publicly available as an open access da-
tabase for researchers. Statistical analysis of these data
and bioinformatics tools may speed-up and provide new
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proteomics and genomics approaches offer remarkable
promising tools to address the molecular level of infor-
mation and their role in infection, which provide an ex-
cellent opportunity to get an insight into the proteins or
genome which may contribute to its inhibition process.
Overview of filariasis
The LF is one of the oldest vector-borne parasitic dis-
ease around the world that is transmitted by more than
four genera of mosquitoes (Aedes, Anopheles—also a prin-
cipal vector for malaria, Culex quinquefasciatus, and Man-
sonia sp)14, each one have different features and trans-
mission procedure. LF is one of the leading causes of
permanent and long-term disability around the world. It
is a disease caused by a group of nematode worms be-
longing to the order “Filariidae” and transmitted to man
by the infective bites of blood-sucking arthropods in man,
and caused by three parasites namely: Wuchereria
bancrofti (Wb), Brugia malayi (Bm) and Brugia timori
(Bt). In all, 90% of these infections are caused by Wb and
remaining by Bm and Bt13, 15. In India, Wb is mainly trans-
mitted by the ubiquitous vector, Cx. quinquefasciatus
which grows on dirty and polluted water, whereas Bm
prevalence is restricted to the rural areas of Kerala16. These
worms occupy the lymphatic system, including the lymph-
nodes, and in chronic cases, these worms lead to the el-
ephantiasis.
Global burden of lymphatic filariasis
The LF is the world’s second leading cause of long-
term disability, suffering, morbidity and several social
and economic burdens to individuals, their families
and nation17–18. It is estimated that 700 million people
are living in the endemic areas of the Southeast Asian
region (SEAR), which contribute >64% of the global
burden19. Several research studies suggest that it causes
the annual economic loss of several billions US$.
Several private pharmaceutical companies have
played very remarkable role in donating billions of doses
of their drugs to the endemic countries during the several
LF elimination programmes running under WHO.
Albendazole, DEC and Ivermectin (Mectizan®) was do-
nated by GlaxoSmithKline, Eisai and Merck & Company
Inc., respectively, for the treatment of LF and onchocer-
ciasis (river blindness) in most of the endemic African
countries for MDA programmes. Recently, Sanofi, Eisai
and Bill & Melinda Gates Foundation committed to do-
nate DEC tablets from 2012 to 202020 and the estimated
cost for MDA per person is US$ 0.05–0.1021.
Global programme to eliminate lymphatic filariasis
(GPELF) and global alliance to eliminate lymphatic filari-
asis (GAELF) estimated that currently, 81 countries are
considered endemic for LF, and about 1.34 billion, persons
are at the risk of infection. According to VI GAELF
meeting of June 2010, 37 countries have completed >5
rounds of MDA at some of the endemic areas. Therefore,
22 million people have been protected with estimated eco-
nomic saving of US$ 24.2 billion. Still approximately >100
million persons are suffering from LF, and it is having a
total global burden of 65% in the SEAR region, and 35%
in Africa region (AFR)22. According to a WHO report, In-
dia, Indonesia and Bangladesh alone contribute >70% of
the infection worldwide. Apart from these countries, six
other countries, such as Maldives, Myanmar, Nepal, Sri
Lanka, Thailand and Timor-Leste are the other endemic
countries, having  more number of LF cases.
Role of bioinformatics in filarial research
Bioinformatics
Bioinformatics is a branch of science, which deals
with the computer-based analysis for the biological
datasets. Currently, biology and computer science are
evolving like close friends which are mutually helping
and influencing each other in the field. Bioinformatics
has accelerated the investigation of the cellular process
to understand the molecular mechanism. It has also ac-
celerated several fields of biological sciences and drug
discovery. In the past few years, bioinformatics ap-
proaches have been used in various fields of biological
sciences to understand and solve the biological problems.
Genomic approach in filarial research
Genomic technology is a powerful technology of
the bioinformatics which is rapidly being used to under-
stand the structure and function of all the genes within
an organism. Genomics help to mark the genes and
other biological features in the entire DNA sequence
of the organism. The field also includes evolutionary
studies, intra-genomic phenomena such as heterosis,
epistasis, pleiotropy and other interactions between
loci and alleles within the genome22. Moreover, drug
targets can be screened or identified using the genomics
approach.
Using bioinformatics approach of phylogenetic analy-
sis Casiraghi et al23 have identified the gene sequence of
mitochondrial cytochrome oxidase-I (COI) from 11 spe-
cies of filarial nematodes and spiruid nematodes. Further,
Hoerauf et al24 found the mutualistic interaction between
the intracellular bacteria (endobacteria) and filarial nema-
todes, which throws light on the filarial chemotherapeu-
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strains could be predicted as Nuchprayoon et al25 had iden-
tified the genetic diversity existing between the Myanmar
and Thai strains of Wb using phylogenetic analysis using
parsimony tool (PAUP).
Recently, nuclear genome draft of the first human
filarial parasites of Bm (95-Mb) has been reported, which
contains 88, 363, 057 bp of assembled sequence with
17.84% of protein coding sequence26. The full genome
data are available at the recent release of NEMBASE4
database. Analysis of these data using genomics approach
can provide significant enrichment in our knowledge to
understand the genetic principles that govern various es-
sential functions for their survival27 which can provide
several fruitful drug targets.
Moreover, miRNAs are involved in various regula-
tions and developmental process of nematodes. Genomics
study can find a variety of genes which regulate or may
take part in central role for miRNA processing. Several
investigators have identified novel functions of miRNAs
in filarial parasites, during the filarial comparison stud-
ies28–29. These miRNAs processing genes may explore
the knowledge about the involvement of various para-
sitic genes of nematodes through the silencing or knock-
down approach30–31, as in the case of Ce could also be
targeted for drug discovery and design.
Proteomic approach in filarial research
The terms ‘Proteomics’ and ‘Proteome’, were first
time used in 1995 for the large-scale study of proteins.
Proteins are nothing but are macromolecules made up of
strings of amino acids linked like a chain which are made
up of 20 amino acids, these combined and formed more
than thousand proteins, with specific shape and function.
In addition, each protein undergoes post-translation modi-
fication that further influences its molecular structure and
functions32. Traditionally, proteomics technology is based
on highly efficient methods of separation using two-di-
mensional-poly acrylamide gel electrophoresis (2D-
PAGE) and modern tools of bioinformatics.
Proteomic analysis of the several stages of Bm has
identified 557 of the 805 Wolbachia endosymbionts from
Bm (wBm) proteins and 11,508 protein coding genes in
the initial draft of Bm. This information may be used to
proteome map using reverse-phase liquid chromatogra-
phy-tandem mass spectroscopy to define various proteins.
Recently, Bennuru et al33 have done the same to define
excretory/secretory (ES) and somatic proteins produced
by the adult, mf and infective stages of larvae.
Since molecular knowledge of protein plays a sig-
nificant role for drug designing and vaccine development34
several investigators have modeled the three-dimensional
structure of novel drug targets for LF and provided the
molecular information of the respective proteins35–37. For
example, in the absence of the crystallographic structure
of Glutathione-S-transferase (GST), Bhargavi et al35 have
modeled the 3-D structure of the GST which was further
studied by Azeez et al38 for the hunt of a better drug. In
this study, potential drugs were identified using virtual
screening, further tested for in vitro study which could be
used for various phases of clinical trials. Other novel drug
targets are also available for which molecular structures
are not yet defined (Table 1). Using bioinformatics ap-
proach these novel drug targets can be modeled, and their
molecular function could be interrupted for nematocidal
effect using rational drug design approach of either ligand-
based drug designing (LBDD) or structure-based drug
designing (SBDD) (Fig. 1).
LBDD is a popular method for drug discovery and
leads optimization. It provides crucial insights into the
interaction between drug target and ligand molecule and
allows us to understand the features of lead molecules for
their biological activity39. This method can also predict
the novel molecular structure with desirable features for
the interaction with the target molecule. For LBDD of
LF, various drugs are available with their target protein
(Table 2). These existing drugs could be re-studied for
3D-quantitative structural activity relationship (QSAR)
and pharmacophore modeling that defines the minimum
necessary structural characteristics of a small molecule
possess to inhibit the target.
SBDD is a rapidly growing method with which many
successes have achieved in recent years40–44. Due to the
explosion of proteomics and genomics various drug tar-
gets have been identified to design a drug. SBDD relies
upon the knowledge of the 3D structure of the target pro-
tein obtained from the experimental method such as X-
ray crystallography, NMR, electron microscopy, etc. If
an experimental method is not available, homology mod-
eling is the approach to build the 3D structure using tar-
get protein sequence45. These macromolecules could be
analyzed for the possible inhibitor binding site identifi-
cation. Based on the binding site, potential inhibitor can
be designed or identified from the small molecule
databases such as ZINC database46, DrugBank47,
ChemBank48, PubChem49, Cambridge structural data-
base50 and various other databases available at
Lignad.Info: Molecule database51 to check the biological
activity of the relevant protein.
Web-based available resources for LF
A database is a web-based resource or collection of
data, which is organized so that various users or research- J Vector Borne Dis 50, September 2013 158
Table 1. Novel drug targets for lymphatic filariasis
S.No. Novel protein targets Protein functions
1. Phosphoglycerate mutase It catalyzes the interconversion of 2- and 3-phosphoglycerate in the glycolytic and
gluconeogenic pathways.
2. Aminoacyl-tRNA synthetase (AARS) It catalyzes the esterification of a specific amino acid or its precursor to one of all its
compatible cognate tRNAs to form an aminoacyl-tRNA.
3. Trehalose-6-phosphate-synthase It plays several physiological functions such as energy reserve, glucose uptake and egg
hatching.
4. Prolyl-4-hydroxylase It catalyzes the hydroxylation of prolines in the X-Pro-Gly repeats of collagen chains, it
is an essential enzyme for the maturation of collagen in nematodes.
5. S-adenosyl-methionine decarboxylase It is a key enzyme in polyamine metabolism and antioxidation.
6. Glutathione-s-transferases (GSTs) GSTs are major phase-II detoxification enzymes and binding proteins.
7. Myristoyl-transferase It plays crucial role in the fatty acid metabolism.
8. Farnesyl-transferase It catalyzes the transfer of a farnesyl residue from farnesyl-pyrophosphate (FPP) to the
thiol of a cysteine side chain of proteins, which carry at the C-terminal the so-called
CAAX-sequence.
9. FAR protein or retinol binding protein It is a structurally novel small helix-rich fatty acid and retinol binding protein. It’s having
a potential role in the generation of pathology, and parasite development.
10. Cystathionine-β-synthase This enzyme acts in a chemical pathway and is responsible for using vitamin B6 to convert
building block of proteins (amino acid) called homocysteine and serine to a molecule
called cystathionine.
11. Prolyl-4-hydroxylase It can alter protein conformation and protein-protein interactions.
12. Transglutaminase Role in the growth, development and maturation of nematodes.
13. Translationally controlled tumor protein It has been implicated in important cellular processes, such as cell growth, cell cycle
progression, and malignant transformation and in the protection of cells against various
stress conditions and apoptosis.
14. Secondary amines and tertiary amines The secondary amines having longer alkyl chain (n >5) would be responsible for eliciting
macro®laricidal activity; and the tertiary amines having dialkyl chain (n = 3) show a vital
role in predominantly micro®laricidal action.
15. Fructose-1,6-bisphosphate aldolase It is a heat-stabile and bi-functional protein that represents the pace-making ancestral
gluconeogenic enzyme. It may be a potential vaccine target.
16. Filarial chitin Chitin metabolism has also been proposed to be a parasite unique target, as the vertebrate
host does not contain chitin.
17. DNA topoisomerase-II It has an important role in DNA replication, repair and transcription.
18. Octopamine (OA) OA plays an important role in the regulation of a number of key processes in nematodes,
including pharyngeal pumping, locomotion and egg-laying.
19. Glutathione reductase It is an important part of the antioxidant system of many living cells. It maintains the
correct intracellular redox balance.
20. Glutathione-s-transferases (GSTs) GSTs are one of the major detoxification systems ubiquitous among eukaryotes and have
been found in a wide range of parasitic helminthes.
21. Glutathione peroxidases (GPXs) GPXs protect the filarial worms from oxidative damage, and are thus important targets
for novel chemotherapy.
22. Eicosanoid It may act locally in the host and modify host-parasite interactions. The production of
these lipid mediators may be one of the strategies for evading host immune responses.
Table 2. Available drugs and their drug targets for lymphatic filariasis
S.No. Drug Drug target
1. Albendazole Tubulin polymerization
2. DEC Cyclo-oxygenase pathway and COX-1
3. Ivermectin Glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria
4 Benzimidazole Tubulin polymerization
5. Levamisole L-subtype nicotinic acetylcholine receptors in nematode muscles
6. Piperazine GABA receptors, presumably causing hyperpolarization of nerve endings, resulting in flaccid paralysis of the worm
7. Mebendazole Colchicine-sensitive site of tubulin
8. Imidazole Tubulin polymerization 159 Sharma et al: Filarial research and role of bioinformatics
ers can access the available data or information at the
same time through the internet worldwide. Biological
database plays an important role in bioinformatics. It of-
fers to the group of scientists or researchers to analyze
the large amount of biological data available for nucle-
otide sequences, amino acid sequences and their 2D or
3D structures for the broad range of organisms and their
drug targets. Currently, there are only few active data-
bases available for LF (Table 3) but comprehensive and
specified database for LF is not available. A specific-drug
target database such as clostridium drug target databse52,
dengue drug target database (http://www.bioinformatics.
org/dengueDTDB/Pages/main.htm) and the TDR
targets database53, there is an urgent need for LF drug
target database to enhance the drug discovery and to avoid
the drug resistance. Some of the important databases
which are available for LF research have been discussed
below.
NEMBASE: NEMBASE54 contains EST datasets for
nematodes, including filarial nematodes. They have the
filarial genome project—a multinational project for the
general information such as filarial biology and pathol-
ogy and genome information such as filarial gene nomen-
clature, filarial genome mapping, and Bm genome survey
sequencing (GSS). Currently, they have added genome
sequencing of wBm and Onchocerca volvulus (Ov) with
the Sanger Institute, NEB and TIGR.
WormBase: WormBase55 is an open access database
and repository for nematode biology which contains the
genome browser for Bm, C. elegans, H. contortus and
other related nematodes. It also contains the gene predic-
tions and orthology assignments from a range of related
nematodes.
FilaDB: It is a database for filarial patients where,
clinico-immuno monitoring and management were de-
veloped for Kasturba Hospital and private practitioners
to screen for filarial infections with the objective to pro-
vide information on an incidence of mf, types of acute,
chronic and occult manifestations, age, sex and distribu-
tion area of filariasis cases. Relapse of filarial infections
if any and compliance in clinico-immuno monitoring and
treatment. These types of open access database may help
researchers to fight with this type of chronic suffering
diseases.
Filarial worm database at Broad Institute: Filarial
worm database at Broad Institute is a newly built data-
base at Broad Institute to study the crucial phenotypic
Fig. 1: Computational approach towards antifilarial drug discovery. J Vector Borne Dis 50, September 2013 160
difference between the closely related filarial species
(http://www.filariasiscenter.org/brugia-malayi-
genomics-and-bioinformatics-resources). It contains the
genome information about the Loa loa, Wb and Ov. Fur-
thermore, it also summarizes the sequence data on
Wolbachia endosymbionts of Wb, Ov and Bm.
Since, filarial diseases are still remaining as a major
public health concern in India. There is a need of com-
prehensive database, which should contain: (a) curated
links between genes relevant to filariasis and their se-
quences in GenBank and SwissProt; (b) sequence homol-
ogy between different filariasis causing genes; (c) pri-
mary and secondary information of pathogens; (d)
availability of various drugs and their targets; (e) ex-
pressed sequence tagged (EST) sequences from different
filarial species; (f) supporting references from published
literatures; and (g) bioinformatics tools to analyze those
data. Database should also contain the epidemiological
data on age and gender-wise incidences of disease, re-
mission and transition rates of disease sequelae.
CONCLUSION
In this review article, we have discussed the current
research and the global burden due to the LF. In India,
LF is one of the major health problems, and contributes
>40% of the global burden and approximately 50% of
the people at risk of getting infection. Here, proper
treatment of patients with MDA and disease-specific
care, patient education and their counseling is also
necessary to create the awareness among the people and
to avoid morbidity of the disease. Since, bioinformatics
has emerged as a promising branch of science, and has a
central role in various fields of life science, we have
reviewed the major contribution of bioinformatics in
filarial research, and found that still we can use
various approaches of bioinformatics to understand this
disease. Various novel drug targets have been listed in
the manuscript, which could be re-examined or re-stud-
ied to understand the disease and to design antifilarial
drugs.
Table 3. Representative online web resources and databases for lymphatic filariasis
S.No. Name Description URL
1. DBEMFDD It is an annotated bibliography for filariasis, http://ideas.repec.org/p/ess/wpaper/id2032.html
diseases database malaria, dengue and diarrheal. It also contains
the findings of the literature survey.
2. FilaDB Database on filaria detection, clinico-immuno http://www.jbtdrc.org/FilaDb.htm
monitoring & management has been developed
for Kasturba Hospital and private practitioners
to screen the filarial infection.
3. NEMBASE2 Contains the EST sequence for Brugia malayi http://www.nematodes.org/nematodeESTs/nembase.html
and other nematodes.
4. Filaria Journal Full and freely access journal of filariasis. http://www.filariajournal.com/
5. Wormbase It is an online database for the biology and http://www.wormbase.org
genome of the Ce and related nematodes.
6. WHO It contains the related publication of filariasis, http://www.who.int/topics/filariasis/en/
reports of elimination programme, control of
neglected tropical diseases and some important links.
7. PHIS It contains the news and updated from filariasis http://umis.doh.gov.ph/fila
elimination programme.
8. Disease database It contains the general information regarding http://www.diseasesdatabase.com/ddb4824.htm
diseases.
9. TDR-lymphatic It contains knowledge about the parasite genomes http://www.who.int/tdrold/diseases/lymphfil/default.htm
filariasis for African lymphatic filariasis and other diseases.
TDR is now focusing on providing capacity to use
the parasite genome data and on supporting
developments in applied genomics and bioinformatics.
10. Filarial worms This database provides the genome sequence http://www.broadinstitute.org/annotation/genome/
database of organisms rapidly and broadly available to filarial_worms/MultiHome.html
the scientific community. 161 Sharma et al: Filarial research and role of bioinformatics
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